Diane Counce, MD
Neurology · Birmingham, ALNPI 1417989740
Payments from drug & device makers
Across 2,834 payments — averaging $495.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$805K
- Lilly USA, LLC$123K
- Amgen$89K
- Sage Therapeutics, LLC$58K
- Biohaven Pharmaceuticals, Inc.$55K
- H. Lundbeck A S$40K
- plus $234K from 54 others
Across 7 payments — averaging $2656.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$12K
- Eli Lilly$7K
What the payments were for
- Consulting fees$84,5129%
- Speaking & faculty fees$719,20480%
- Grants$440%
- Travel & lodging$50,8326%
- Food & beverage$40,5095%
- Education$2560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$273,029
- UBRELVY$158,368
- AIMOVIG$87,550
- QULIPTA$71,954
- EMGALITY$71,158
- NURTEC ODT$45,904
- REYVOW$40,275
- VALTOCO$30,287
- VYEPTI$25,373
- AJOVY$23,390
- XCOPRI$16,924
- Trudhesa$11,780
- Symbravo$6,901
- Briviact$4,410
- Cenobamate$3,400
- Nayzilam$825
- VNS Therapy$652
- Epidiolex$267
- Jornay PM 20mg capsules (Bottle of 100)$253
- ZEPOSIA$183
How this compares
$1,403,246 in reported general payments places this provider in the 95th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 117 | $1,036,278 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 37 | $380,326 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 53 | $254,010 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 23 | $186,513 |
| Nurtec OdtRimegepant Sulfate | 56 | $98,707 |
| Emgality PenGalcanezumab-Gnlm | 118 | $83,120 |
| UbrelvyUbrogepant | 58 | $81,645 |
| Aimovig AutoinjectorErenumab-Aooe | 98 | $79,213 |
| Lacosamide | 182 | $39,180 |
| Lamictal XrLamotrigine | 12 | $33,512 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 19 | $24,956 |
| FycompaPerampanel | 21 | $24,789 |
| NayzilamMidazolam | 23 | $24,383 |
| BriviactBrivaracetam | 15 | $20,440 |
| CambiaDiclofenac Potassium | 13 | $19,176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $125 | $1,036,278117 claims |
| PfizerPanzyga, Nurtec Odt | $37,376 | $479,03393 claims |
| AbbVieUbrelvy, Qulipta | $804,617 | $98,59574 claims |
| UCB, Inc.Nayzilam, Briviact, Neupro, Vimpat | $9,725 | $76,18865 claims |
| Eisai Inc.Fycompa, Dayvigo | $838 | $35,93850 claims |
| Assertio Therapeutics, Inc.Cambia | $299 | $19,17613 claims |
| SK Life Science, Inc.Xcopri | $21,494 | $17,01616 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $90 | $8,58648 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 neurology providers in Alabama.
Other neurology in Birmingham
- Emily RiserBirmingham$7.1M
- Louis NaborsBirmingham$3.2M
- Khurram BashirBirmingham$2.8M
- David GeldmacherBirmingham$2.6M
- Victor SungBirmingham$2M
- Mina LobbousBirmingham$1.8M
- Marissa Natelson LoveBirmingham$792K
- David StandaertBirmingham$787K
- Marissa DeanBirmingham$592K
- Natividad StoverBirmingham$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.